Global Human Chorionic Gonadotrophin (HCG) Market Growth (Status and Outlook) 2025-2031

The global Human Chorionic Gonadotrophin (HCG) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Human Chorionic Gonadotrophin (HCG) is a hormone produced during pregnancy. It is used as an indicator in pregnancy tests and can also be administered medically for various purposes.

United States market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Human Chorionic Gonadotrophin (HCG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Human Chorionic Gonadotrophin (HCG) players cover Qingdao Kangyuan Pharmaceutical Co., Ltd., Ningbo Renjian Pharmaceutical Group Co., Ltd., Jiangxi Haoran Biopharmaceutical Co., Ltd., Shanghai Tianwei Biopharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Human Chorionic Gonadotrophin (HCG) Industry Forecast” looks at past sales and reviews total world Human Chorionic Gonadotrophin (HCG) sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Chorionic Gonadotrophin (HCG) sales for 2025 through 2031. With Human Chorionic Gonadotrophin (HCG) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Chorionic Gonadotrophin (HCG) industry.

This Insight Report provides a comprehensive analysis of the global Human Chorionic Gonadotrophin (HCG) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human Chorionic Gonadotrophin (HCG) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Chorionic Gonadotrophin (HCG) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Chorionic Gonadotrophin (HCG) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Chorionic Gonadotrophin (HCG).

This report presents a comprehensive overview, market shares, and growth opportunities of Human Chorionic Gonadotrophin (HCG) market by product type, application, key players and key regions and countries.

Segmentation by Type:
u-hCG
r-hCG

Segmentation by Application:
Drug
Pregnancy Test Paper
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Qingdao Kangyuan Pharmaceutical Co., Ltd.
Ningbo Renjian Pharmaceutical Group Co., Ltd.
Jiangxi Haoran Biopharmaceutical Co., Ltd.
Shanghai Tianwei Biopharmaceutical Co., Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver.